News

Article

FDA approves expanded label for fluocinolone acetonide intravitreal implant

Author(s):

Key Takeaways

  • The FDA approved an expanded label for ILUVIEN, now including chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
  • ILUVIEN is already approved for diabetic macular edema (DME) and NIU-PS in 17 European countries.
SHOW MORE

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

Image credit: AdobeStock/ronstik

(Image credit: AdobeStock/ronstik)

The US Food and Drug Administration (FDA) has approved an expanded label for fluocinolone acetonide intravitreal implant (ILUVIEN) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). In addition to the expansion of this label, the approval includes updates to the label including to the Warnings and Precautions section. This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

ANI previously announced that it extended its supply agreement for ILUVIEN with a subsidiary of Siegfried Holding AG (Seigfried) through 2029. Siegfried and ANI also agreed to upgrade equipment on the existing manufacturing line and significantly expand capacity.

Indications

ILUVIEN is a corticosteroid indicated for:

  • the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
  • the treatment of chronic NIU-PS of the eye.

Contraindications

ILUVIEN is contraindicated in patients

  • with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases;
  • with glaucoma who have cup to disc ratios of greater than 0.8;
  • with known hypersensitivity to any components of this product.
  • Additional information on safety information and adverse events can be found in the company press release.
Reference:
1. ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label. ANI Pharmaceuticals, Inc. March 14, 2025. Accessed March 18, 2025. https://www.globenewswire.com/news-release/2025/03/14/3042856/0/en/ANI-Pharmaceuticals-Announces-FDA-Approval-for-Expansion-of-ILUVIEN-Label.html

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.